Evidence map›Paper›PMID 33079319›Full record

ArticleCardiovascular drugs and therapy2021

Rapid Lipid Modification of Endothelial Cell Membranes in Cardiac Ischemia/Reperfusion Injury: a Novel Therapeutic Strategy to Reduce Infarct Size.

Claudio Maldonado, Mai-Dung Nguyen, Phillip Bauer, Shunichi Nakamura, Syed J Khundmiri, Gustavo Perez-Abadia, Heather L Stowers, Wen-Jian Wu, Xian-Liang Tang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular drugs and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Claudio MaldonadoEndoProtech, Inc., Louisville, KY, 40204, USA. cjmald01@louisville.edu.ORCID 0000-0002-2034-2273
Mai-Dung NguyenEndoProtech, Inc., Louisville, KY, 40204, USA.
Phillip BauerEndoProtech, Inc., Louisville, KY, 40204, USA.
Shunichi NakamuraCardiovascular Medicine, Nippon Medical School, Tokyo, Japan.ORCID 0000-0003-2211-2698
Syed J KhundmiriDepartment of Physiology and Biophysics, Howard University, Washington, DC, 20059, USA.ORCID 0000-0002-0364-0412
Gustavo Perez-AbadiaEndoProtech, Inc., Louisville, KY, 40204, USA.ORCID 0000-0001-9297-9022
Heather L StowersDepartment of Medicine, Division of Cardiovascular Medicine, University of Louisville, Louisville, KY, 40202, USA.
Wen-Jian WuDepartment of Medicine, Division of Cardiovascular Medicine, University of Louisville, Louisville, KY, 40202, USA.
Xian-Liang TangDepartment of Medicine, Division of Cardiovascular Medicine, University of Louisville, Louisville, KY, 40202, USA.ORCID 0000-0002-5987-340X
University of Louisville · USEndoProtech (United States) · USHoward University · USNippon Medical School · JP

Funding

A Novel Lipotherapy to Reduce Infarct Size Following Myocardial InfarctionR43HL132649 · NHLBI · ENDOPROTECH, INC. · PI BAUER, PHILIP, MALDONADO, CLAUDIO · 2016 to 2016
$225k
NHLBI NIH HHS R43 HL132649
6 · The paper itself

Abstract

purposePlasma membranes constitute a gathering point for lipids and signaling proteins. Lipids are known to regulate the location and activity of signaling proteins under physiological and pathophysiological conditions. Membrane lipid therapies (MLTs) that gradually modify lipid content of plasma membranes have been developed to treat chronic disease; however, no MLTs have been developed to treat acute conditions such as reperfusion injury following myocardial infarction (MI) and percutaneous coronary intervention (PCI). A fusogenic nanoliposome (FNL) that rapidly incorporates exogenous unsaturated lipids into endothelial cell (EC) membranes was developed to attenuate reperfusion-induced protein signaling. We hypothesized that administration of intracoronary (IC) FNL-MLT interferes with EC membrane protein signaling, leading to reduced microvascular dysfunction and infarct size (IS).

methodsUsing a myocardial ischemia/reperfusion swine model, the efficacy of FNL-MLT in reducing IS following a 60-min coronary artery occlusion was tested. Animals were randomized to receive IC Ringer's lactate solution with or without 10 mg/mL/min of FNLs for 10 min prior to reperfusion (n = 6 per group).

resultsThe IC FNL-MLT reduced IS (25.45 ± 16.4% vs. 49.7 ± 14.1%, P < 0.02) and enhanced regional myocardial blood flow (RMBF) in the ischemic zone at 15 min of reperfusion (2.13 ± 1.48 mL/min/g vs. 0.70 ± 0.43 mL/min/g, P < 0.001). The total cumulative plasma levels of the cardiac injury biomarker cardiac troponin I (cTnI) were trending downward but were not significant (999.3 ± 38.7 ng/mL vs. 1456.5 ± 64.8 ng/mL, P = 0.1867). However, plasma levels of heart-specific fatty acid binding protein (hFABP), another injury biomarker, were reduced at 2 h of reperfusion (70.3 ± 38.0 ng/mL vs. 137.3 ± 58.2 ng/mL, P = 0.0115). 

conclusionThe IC FNL-MLT reduced IS compared to vehicle in this swine model. The FNL-MLT maybe a promising adjuvant to PCI in the treatment of acute MI.

Indexed as

AnimalsDisease Models, AnimalDrug CarriersEndothelial CellsFemaleLiposomesMembrane LipidsMiceMyocardial Reperfusion InjuryNanoparticlesSignal TransductionSwineDrug CarriersLiposomesMembrane LipidsEndotheliumIschemia/reperfusionLipid raftsLiposomesMembrane lipid therapyMyocardial infarctionPercutaneous coronary intervention

Identifiers

PMID33079319
PMCPMC8376233
OpenAlexW3093357057

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.